2023
Cancer Care Report
Data collected in 2022 and reported in 2023
Each year we look at cancer cases locally and nationally in order to understand trends, support cancer research, measure progress in prevention efforts, and to improve cancer outcomes. As an accredited organization we have proven ourselves through legitimate third parties that we meet or exceed strict quality standards. •
Accredited with commendation by the Commission on Cancer (CoC) of the American College of Surgeons (ACoS) as a Community Hospital Comprehensive Cancer Program.
•
The Radiation Oncology Department is accredited by the American College of Radiology (ACR).
•
Fully accredited by the National Accreditation Program for Breast Centers (NAPBC), a program administered by the American College of Surgeons.
•
Member of the American Society of Clinical Oncology (ASCO).
•
Member of the American Society for Radiation Oncology (ASTRO).
•
Gold seal of approval from The Joint Commission.
•
Participates in the Michigan Radiation Oncology Quality Consortium and the Cancer Research Consortium of West Michigan.
Read on to learn more about cancer cases from 2022 in Michigan, the United States, and at Corewell Health Lakeland Hospitals specifically.
spectrumhealthlakeland.org/cancer-care
2023 Cancer Care Report
Statistical summary and review of registry data 2022
Non-analytic cases are those that were diagnosed and received all first course treatment elsewhere, and came to Corewell Health for subsequent treatment for either recurrence or persistence of their disease.
In 2022, 1,339 cases were added to the Corewell Health in Southwest Michigan Cancer Registry. Of these cases, 1,206 cases were considered analytic, which means that they received all or part of their first course treatment locally, or were diagnosed by Corewell Health in Southwest Michigan and received all first course treatment elsewhere. The number of cisgender males were 601 (44.89%), cisgender female were 736 (54.97%), transgender female was one (0.7%), and transgender male was one (0.7%). Patients diagnosed at age 60 years or older accounted for 72.97% of cases. Patients 30 through 59 years of age accounted for 25.16%, while 1.87% of cases were 29 years old or younger. The mean age of cancer patients in 2022 was 65.
Figure 1a 2022 ratio of female to male patients
.07%
Transgender male at birth
54.97% 44.89% 736 Females
601 Males
Figure 1b 2022 age distribution
.07%
72.97% 25.16%
Transgender female at birth
60 Years and older
Ages 30-59
1.87%
Age 29 and younger
Figure 2 Percent distribution of Corewell Health Lakeland Hospitals’ 2022 cancer cases by age decade
Percent distribution
35% 27.86% 28.98%
30% 25% 20%
15.39%
15% 10% 5% 0%
1.87% 0-29
4.70%
5.07%
30-39
40-49
13.52%
2.61% 50-59
60-69
Age decade
70-79
Page 1
80-89
90+
Page 2
2023 Cancer Care Report
Table 1 Site distribution by stage for the four most common cancer sites at Corewell Health Lakeland Hospitals* Cases
Stage 0
Stage I
Stage II
Stage III
Stage IV
UNK Staged
Breast
185
29
108
27
12
7
2
Lung
181
0
52
13
29
85
2
Prostate
134
0
31
45
26
20
12
Colorectal
109
8
20
19
29
29
4
Table 2 Comparison of four most common cancer sites, Corewell Health Lakeland Hospitals, state of Michigan, and United States
Corewell Health Lakeland Hospitals
Michigan
United States
Rank
Cases
% of Total
Rank
% of Total
Rank
% of Total
Breast
1
185
13.81%
2
14.28%
1
15.00%
Lung
2
181
13.51%
3
13.95%
3
12.34%
Prostate
3
134
10.00%
1
14.78%
2
13.99%
Colon/rectum
4
109
8.14%
4
7.48%
4
7.87%
Site
*American Cancer Society. Cancer Facts & Figures 2022. Atlanta: American Cancer Society; 2022, pg 4-5.
Table 3 Comparison of percent distribution of Corewell Health Lakeland Hospitals 2022 cancer cases and United States data by gender and four most common cancer sites
Male Cancer Cases Site
Female Cancer Cases
United States*
Lakeland
United States*
Lakeland
Breast
0.27%
0.33%
30.79%
24.86%
Prostate
27.30%
22.29%
NA
NA
Lung
11.99%
14.47%
12.71%
12.77%
Colorectal
8.20%
8.48%
7.52%
7.88%
*American Cancer Society. Cancer Facts & Figures 2022. Atlanta: American Cancer Society; 2022 pg 4.
2023 Cancer Care Report
Page 3
Figure 3 Comparison of percent distributions of Corewell Health Lakeland Hospitals three most common female and male cancer sites for 2022 and United States data*
Female
35% 30.79%
30% 25%
30% 24.90%
25%
20%
27.30% 22.30%
20%
15%
12.80%
14.50%
15%
12.71%
10%
7.90%
7.52%
5% 0%
Male
35%
11.99%
10%
8.50%
8.20%
5%
Breast
Lung
Corewell Health Lakeland Hospitals
Colorectal
0%
United States*
Prostate
Lung
Colorectal
*American Cancer Society. Cancer Facts & Figures 2022. Atlanta: American Cancer Society; 2022, pg 4.
Figure 4 Comparison of percent distribution of Corewell Health Lakeland Hospitals’ 2022 cancer cases by gender Breast - 183 (25%)
Prostate - 134 (22%)
Lung & Bronchus - 94 (13%)
Lung & Bronchus - 87 (15%)
Uterine Corpus - 48 (6%)
Colon & Rectum - 51 (9%)
Colon & Rectum - 58 (8%)
Non-Hodgkin Lymphoma - 16 (3%)
Kidney & Renal Pelvis - 15 (2%)
Urinary Bladder - 38 (6%)
Melanoma of the Skin - 20 (3%)
Kidney & Renal Pelvis - 29 (5%)
Leukemia - 17 (2%)
Leukemia - 18 (3%)
Non-Hodgkin Lymphoma - 12 (2%)
Melanoma of the Skin - 22 (4%)
Thyroid - 8 (1%)
Oral Cavity & Pharynx - 20 (3%)
Ovary - 8 (1%)
Pancreas - 21 (3%)
All Other Sites - 273 (37%)
All Other Sites - 165 (27%)
Female
Male
Page 4
2023 Cancer Care Report
Figure 5a Distribution of Corewell Health Lakeland Hospitals cancer cases by county
All other Michigan Counties
.67%
Lake Michigan
Van Buren County
5.75% Berrien County
83.20%
Cass County
9.04%
Out of State 1.34%
Figure 5b Distribution of Corewell Health Lakeland Hospitals cancer cases by city (Berrien, Cass, Van Buren counties) 20%
19.19%
16% 13.20% 12.99%
14% 12% 10% 8%
6.79%
6%
5.89%
5.30% 5.00%
257
178
174
91
79
71
67
52
48
32
30
27
23
20
18
Stevensville
Dowagiac
Berrien Springs
Coloma
Buchanan
Watervliet
Hartford
Bridgman
Cassopolis
Eau Claire
Baroda
Three Oaks
0%
2.38% 2.24% 2.00% 1.71% 1.49% 1.34%
Niles
2%
3.88% 3.58%
St. Joseph
4%
Benton Harbor
Percent distribution
18%
City
2023 Cancer Care Report
Figure 6 Distribution of total cancer cases by primary site Breast
185
Lung and Bronchus Lung and Bronchus
181
Breast Prostate
Prostate
134
BenignBrain/Cranial Brain/Cranial Nerves Benign Nerves
106
Colon
76
Female Female GenitalGenital System System
74
Colon
*CIN III Non-Hodgkins Lymphoma
68
Bladder
46
& R enal Pelvis Kidney &Kidney Renal Pelvis
44
Bladder
Melanoma
42
*CIN III
Leukemia
36
Melanoma
Pancreas
34
Rectum and rectosigmoid Benign Endocrine
33
Miscellaneous
31
Oral Cavity &Benign PharynxEndocrine
30
Pancreas Non-Hodgkins Lymphoma
28
Rectum Oral Cavity & Pharynx
26
Myeloma
24
Esophagus
21
Malignant Thyroid/Endocrine Liver & Intrahepatic Bile Duct
17
Esophagus
Larynx
16
Liver & Intrahepatic Bile Duct Malignant Thyroid/Endocrine
14
Larynx Brain/Cranial Nerves Malignant
12
Malignant Brain/Cranial Nerves Stomach
12
Anus, Anal Canal & Anorectum Small Intestine
10
Soft Tissue Anus, Anal Canal & Anorectum
8
Leukemia
Myeloma
Stomach Miscellaneous
Gallbladder
Testis
7
Small Intestine Hodgkin Lymphoma
3
Testis
Gallbladder
3
Mesothelioma Mesothelioma Hodgkin LymphomaBone/Joint
2
Bone/Joint
Soft Tissue
1 1
0 is accessioned by agreement, 50 but for 2022 the collection 100 of this data was mandated 150by the State of Michigan200 *CIN III (non-invasive cervical severe dysplasia)
Page 5
Page 6
2023 Cancer Care Report
Table 4 Summary: By body, system, and gender Primary Site
Total
Percent
Male
Percent
Female
Percent
BRAIN & OTHER NERVOUS SYSTEM
118
8.8%
42
6.8%
76
10.3%
Brain
19
1.4%
12
2.0%
7
0.9%
Cranial Nerves other Nervous System
99
7.4%
30
4.8%
69
9.4%
BONES & JOINTS
1
0.1%
0
0.0%
1
0.1%
BREAST
185
13.8%
2
0.3%
183
24.8%
DIGESTIVE SYSTEM
218
16.3%
121
20.1%
97
13.2%
Anus, Anal Canal & Anorectum
8
0.6%
3
0.5%
5
0.7%
Colon Excluding Rectum
76
5.7%
31
5.2%
45
6.1%
Esophagus
21
1.6%
20
3.3%
1
0.1%
Gallbladder
3
0.2%
0
0.0%
3
0.4%
Liver & Intrahepeatic Bile Duct
17
1.3%
9
1.5%
8
1.1%
Rectum & Rectosigmoid
33
2.5%
20
3.3%
13
1.8%
Small Intestine
10
0.7%
5
0.8%
5
0.7%
Stomach
12
0.9%
11
1.8%
1
0.1%
Other Biliary
3
0.2%
1
0.2%
2
0.3%
Pancreas
34
2.5%
21
3.5%
13
1.8%
Peritoneum, Omentum & Mecenter
1
0.1%
0
0.0%
1
0.1%
ENDOCRINE SYSTEM
44
3.3%
14
2.3%
30
4.1%
Thyroid
12
0.9%
4
0.7%
8
1.1%
Other Endocrine including Thymus
32
2.4%
10
1.7%
22
3.0%
EYE & ORBIT
1
0.1%
0
0.0%
1
0.1%
FEMALE GENITAL SYSTEM
142
10.6%
0
0.0%
142
19.1%
Cervix Uteri
78
5.8%
0
0.0%
78
10.4%
Corpus & Uterus, NOS
48
3.6%
0
0.0%
48
6.6%
Ovary
8
0.6%
0
0.0%
8
1.1%
Vagina
1
0.1%
0
0.0%
1
0.1%
Vulva
6
0.4%
0
0.0%
6
0.8%
Other Female Genital Organs
1
0.1%
0
0.0%
1
0.1%
LEUKEMIA
35
2.7%
18
3.0%
17
2.4%
Lymphocytic Leukemia
19
1.5%
9
1.5%
10
1.5%
Myeloid & Monocytic Leukemia
15
1.1%
8
1.3%
7
0.9%
Other Leukemia
1
0.1%
1
0.2%
0
0.0%
2023 Cancer Care Report
Page 7
Table 4 (continued) Summary: By body, system, and gender Primary Site
Total
Percent
Male
Percent
Female
Percent
LYMPHOMA
31
2.3%
18
3.0%
13
1.8%
Hodgkins Lymphoma
3
0.2%
2
0.3%
1
0.1%
Non-Hodgkin Lymphoma
28
2.1%
16
2.7%
12
1.6%
MALE GENITAL SYSTEM
141
10.5%
141
23.5%
0
0.0%
Prostate
134
10.0%
134
22.3%
0
0.0%
Testis
7
0.5%
7
1.2%
0
0.0%
MESOTHELIOMA
2
0.1%
2
0.3%
0
0.0%
MYELOMA
24
1.8%
15
2.5%
9
1.2%
ORAL CAVITY & PHARYNX
26
1.9%
20
3.3%
6
0.8%
Tongue
13
1.0%
12
2.0%
1
0.1%
Salivary Glands
2
0.1%
1
0.2%
1
0.1%
Floor of Mouth
1
0.1%
1
0.2%
0
0.0%
Gum & Other Mouth
2
0.1%
1
0.2%
1
0.1%
Nasopharynx
1
0.1%
1
0.2%
0
0.0%
Tonsil
7
0.5%
4
0.7%
3
0.4%
RESPIRATORY SYSTEM
198
14.8%
100
16.6%
98
13.3%
Larynx
16
1.2%
13
2.2%
3
0.4%
Lung & Bronchus
181
13.5%
87
14.5%
94
12.8%
Trachea, Mediastinum and Other Respiratory Organs
1
0.1%
0
0.0%
1
0.1%
SKIN EXCLUDING BASAL & SQUAMOUS
45
3.3%
24
4.0%
21
2.8%
Melanoma - Skin
42
3.1%
22
3.7%
20
2.7%
Other Non=Epithelial Skin
3
0.2%
2
0.3%
1
0.1%
SOFT TISSUE (including heart)
1
0.1%
0
0.0%
1
0.1%
URINARY SYSTEM
95
7.1%
70
11.6%
25
3.4%
Kidney & Renal Pelvis
44
3.3%
29
4.8%
15
2.0%
Urinary Bladder
46
3.4%
38
6.3%
8
1.1%
Ureter
5
0.4%
3
0.5%
2
0.3%
MISCELLANEOUS
31
2.3%
14
2.3%
17
2.3%
1
0.1%
1
.2%
1
0.0%
Acute Myeloid Leukemia w/ Mutated RUNX1 Total
1,339
602
737